Scientific Advisory Board
Our Cross-Disciplinary Scientific Advisory Board plays a key role in advising and collaborating with the Company to assess and evaluate potential business development opportunities. The Board is composed of four external advisors who bring extensive experience in advancing therapies to patients and in driving scientific and commercial innovation across the industry.
Seasoned Industry Leaders to Augment our BD Search and Due Diligence
Scott Brun, MD
- Venture Partner, Abingworth (current)
- Board member, Jasper Therapeutics and Cabaletta Bio, (current)
- Member. Bain Advisory Network (current)
- Sr Med Advisor, Horizon
- Head of Scientific Affairs, AbbVie Ventures, and Pharmaceutical Development, AbbVie
- Residency in ophthalmology, Harvard
Rob Lenz, MD, PhD
- Board member, NovaBridge Biosciences (current)
- EVP, Head of R&D, Neumora
- SVP, Head of Global Development, Amgen
- Head of Center for Design & Analysis, Amgen
- DVP, Neuroscience, Abbott
- Residency in neurology, UCLA
Elaine Sorg
- Board member, CSL (current)
- Senior Advisor, BCG (current)
- SVP and President, US Commercial Operations, AbbVie
- President, US Immunology, AbbVie
- Brand Leader, Lilly
- BS, Pharmacy, Purdue
- Postgraduate certifications from Univ. of Chicago Booth School of Management and Harvard Business School
Nancy Valente, MD
- Chief Development Officer, Xencor (currently Sr Advisor)
- Board member, Immatics
- Board member, Myovant
- SVP, Head of Global Hematology and Oncology Product Development (co-lead), Genentech/Roche
- Fellowships in hematology, Stanford, and oncology, UCSF